Patents by Inventor Christopher Thomas Brain

Christopher Thomas Brain has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATION COMPRISING A CYCLIN DEPENDENT KINASE 4 OR CYCLIN DEPENDENT KINASE (CDK4/6) INHIBITOR FOR TREATING CANCER
    Publication number: 20130035336
    Abstract: A combination of a CDK4/8 inhibitor and an mTOR inhibitor for the treatment of cancer.
    Type: Application
    Filed: April 12, 2011
    Publication date: February 7, 2013
    Applicant: Novartis AG
    Inventors: Maria Borland, Christopher Thomas Brain, Shivang Doshi, Sunkyu Kim, Jianguo Ma, Josh Murtie, Hong Zhang
  • Pyrazole derivatives
    Patent number: 8367687
    Abstract: The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of diseases, particularly pyrazole compounds and derivatives are described which inhibit protein kinases. The organic compounds are useful in treating proliferative disease.
    Type: Grant
    Filed: December 8, 2008
    Date of Patent: February 5, 2013
    Assignees: Novartis AG, Astex Therapeutics Ltd.
    Inventors: Christopher Thomas Brain, Moo Sung, Young Shin Cho, Ying Hou
  • Pyrrolopyrimidine compounds and their uses
    Patent number: 8324225
    Abstract: The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of diseases, particularly pyrrolopyrimidine compounds and derivatives are described which inhibit protein kinases. The organic compounds are useful in treating proliferative disease.
    Type: Grant
    Filed: May 24, 2007
    Date of Patent: December 4, 2012
    Assignees: Novartis AG, Astex Therapeutics Limited
    Inventors: Christopher Thomas Brain, Moo Je Sung, Gebhard Thoma
  • PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES
    Publication number: 20120207763
    Abstract: The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of diseases, particularly pyrrolopyrimidine compounds and derivatives are described which inhibit protein kinases. The organic compounds are useful in treating proliferative disease.
    Type: Application
    Filed: April 20, 2012
    Publication date: August 16, 2012
    Applicants: ASTEX THERAPEUTICS LIMITED, NOVARTIS AG
    Inventors: Christopher Thomas BRAIN, Moo Je SUNG, Gebhard THOMA
  • QUINAZOLINONE DERIVATIVES USEFUL AS VANILLOID ANTAGONISTS
    Publication number: 20120184571
    Abstract: The present invention relates to the use of a quinazolinone compound of the formula (I) wherein R1, R2, R3, R4, R5 and m are as defined in the specification and in the claims, in free form or in salt form, and, where possible, in acid addition salt form, as a vanilloid.
    Type: Application
    Filed: March 29, 2012
    Publication date: July 19, 2012
    Inventors: Timothy John RITCHIE, Andrew James Culshaw, Christopher Thomas Brain, Edward Karol Dziadulewicz, Terance William Hart
  • Quinazolinone derivatives useful as vanilloid antagonists
    Patent number: 8211902
    Abstract: The present invention relates to the use of a quinazolinone compound of the formula (I) wherein R1, R2, R3, R4, R5 and m are as defined in the specification and in the claims, in free form or in salt form, and, where possible, in acid addition salt form, as a vanilloid.
    Type: Grant
    Filed: April 19, 2011
    Date of Patent: July 3, 2012
    Assignee: Novartis AG
    Inventors: Timothy John Ritchie, Andrew James Culshaw, Christopher Thomas Brain, Edward Karol Dziadulewicz, Terance William Hart
  • IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES
    Publication number: 20120101064
    Abstract: The invention provides compounds of the formula (I): and salts, tautomers, solvates and N-oxides thereof; wherein Q is CH or N; X is N, N+—O? or CR3; Y is N, N+—O? or CR3a; R1 and R2 are independently selected from hydrogen and various substituents as defined in the claims; or R1 and R2 together with the atoms to which they are attached, link to form an optionally substituted carbocyclic or heterocyclic aromatic or non-aromatic ring of 4 to 7 members; R3 is selected from hydrogen and various substituents; and R3a is selected from hydrogen and various substituents as defined in the claims. Also provided are pharmaceutical compositions containing the compounds of formula (I), processes for making the compounds and the medical uses of the compounds. The compounds of formula (I) have activity as inhibitors of CDK kinases and are useful in the treatment of inter alia proliferative diseases such as cancers.
    Type: Application
    Filed: April 30, 2010
    Publication date: April 26, 2012
    Applicants: Astex Therapeutics Limited, Novartis AG
    Inventors: Steven Howard, Paul Neil Mortenson, Steven Douglas Hiscock, Alison Jo-Anne Woolford, Andrew James Woodhead, Gianni Chessari, Marc O'reilly, Miles Stuart Congreve, Claudio Dagostin, Young Shin Cho, Fan Yang, Christine Hiu-Tung Chen, Christopher Thomas Brain, Bharat Lagu, Yaping Wang, Sunkyu Kim, John Grialdes, Michael Joseph Luzzio, Lawrence Blas Perez
  • QUINAZOLINONE DERIVATIVES USEFUL AS VANILLOID ANTAGONISTS
    Publication number: 20110195983
    Abstract: The present invention relates to the use of a quinazolinone compound of the formula (I) wherein R1, R2, R3, R4, R5 and m are as defined in the specification and in the claims, in free form or in salt form, and, where possible, in acid addition salt form, as a vanilloid.
    Type: Application
    Filed: April 19, 2011
    Publication date: August 11, 2011
    Inventors: Timothy John Ritchie, Andrew James Culshaw, Christopher Thomas Brain, Edward Karol Dziadulewicz, Terance William Hart
  • PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES
    Publication number: 20110152244
    Abstract: The disclosed compounds relate to treatments and therapies for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention or amelioration of one or more symptoms of cancer, transplant rejections, and autoimmune diseases. Furthermore, there is a need for methods for modulating the activity of protein kinases, such as CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8 and CDK9, using the compounds provided herein.
    Type: Application
    Filed: August 20, 2009
    Publication date: June 23, 2011
    Applicants: NOVARTIS AG, ASTEX THERAPEUTICS LTD.
    Inventors: Gilbert Besong, Christopher Thomas Brain, Clinton A. Brooks, Miles Stuart Congreve, Claudio Dagostin, Guo He, Ying Huo, Steven Howard, Yue Li, Yipin Lu, Paul Morteson, Troy Smith, Moo Sung, Steven Woodhead, Wojciech Wrona
  • Pyrazole Derivatives
    Publication number: 20100280033
    Abstract: The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of diseases, particularly pyrazole compounds and derivatives are described which inhibit protein kinases. The organic compounds are useful in treating proliferative disease.
    Type: Application
    Filed: December 8, 2008
    Publication date: November 4, 2010
    Inventors: Christopher Thomas Brain, Moo Sung, Young Shin Cho, Ying Hou
  • Chromone derivatives useful as antagonists of VR1 receptors
    Patent number: 7732435
    Abstract: The invention relates to novel heterocyclic compounds of the formula in which all of the variables are as defined in the specification, in free form or in salt form, to their preparation, to their use as medicaments and to medicaments comprising them.
    Type: Grant
    Filed: December 5, 2006
    Date of Patent: June 8, 2010
    Assignee: Novartis AG
    Inventors: Andrew James Culshaw, Christopher Thomas Brain, Edward Karol Dziadulewicz, Lee Edwards, Terance William Hart, Timothy John Ritchie
  • PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES
    Publication number: 20100105653
    Abstract: The disclosed compounds relate to treatments and therapies for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention or amelioration of one or more symptoms of cancer, transplant rejections, and autoimmune diseases. Furthermore, there is a need for methods for modulating the activity of protein kinases, such as CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8 and CDK9, using the compounds provided herein.
    Type: Application
    Filed: August 21, 2009
    Publication date: April 29, 2010
    Inventors: Gilbert Besong, Christopher Thomas Brain, Clinton A. Brooks, Miles Stuart Congreve, Claudio Dagostin, Guo He, Ying Huo, Steven Howard, Yue Li, Yipin Lu, Paul Mortenson, Troy Smith, Moo Je Sung, Steven Woodhead, Wojciech Wrona
  • Pyrrolopyrimidine Compounds and Their Uses
    Publication number: 20090318441
    Abstract: The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of diseases, particularly pyrrolopyrimidine compounds and derivatives are described which inhibit protein kinases. The organic compounds are useful in treating proliferative disease.
    Type: Application
    Filed: May 24, 2007
    Publication date: December 24, 2009
    Inventors: Christopher Thomas Brain, Moo Je Sung, Gebhard Thoma
  • Trisubstituted Quinazolinone Derivatives as Vanilloid Antagonists
    Publication number: 20090082365
    Abstract: The present invention relates to quinazolinone compounds of the formula wherein R2, R3, R5, R6, R7 and R8 are as defined in the specification and in the claims, in free form or in salt form, processes for their preparation and their use as pharmaceuticals, particularly in the treatment of disorders ameliorated by administration of TRPV1 antagonists.
    Type: Application
    Filed: December 6, 2006
    Publication date: March 26, 2009
    Inventors: Gurdip Bhalay, Andrew James Culshaw, Edward Karol Dziadulewicz, Christopher Thomas Brain, Timothy John Ritchie, David Beattie, Kamlesh Jagdis Bala, Alice Brewer, Glyn Hughes
  • Quinazolinone Derivatives as Vanilloid Antagonists
    Publication number: 20080318940
    Abstract: The invention relates to quinazolinone compounds of the formula wherein the R groups are defined in the specification, processes for their preparation and their use as pharmaceuticals, particularly in the treatment of disorders ameliorated by administration of TRPV1 antagonists.
    Type: Application
    Filed: December 6, 2006
    Publication date: December 25, 2008
    Inventors: Edward Karol Dziadulewicz, Christopher Thomas Brain, Timothy John Ritchie, Andrew James Culshaw
  • Chromone Derivatives Useful as Antagonists of Vr1 Receptors
    Publication number: 20080312316
    Abstract: The invention relates to novel heterocyclic compounds of the formula in which all of the variables are as defined in the specification, in free form or in salt form, to their preparation, to their use as medicaments and to medicaments comprising them.
    Type: Application
    Filed: December 5, 2006
    Publication date: December 18, 2008
    Inventors: Andrew James Culshaw, Christopher Thomas Brain, Edward Karol Dziadulewicz, Lee Edwards, Terance William Hart, Timothy John Ritchie
  • Quinazolinone Derivatives Useful as Vanilloid Antagonists
    Publication number: 20080194595
    Abstract: The present invention relates to the use of a quinazolinone compound of the formula (I) wherein R1, R2, R3, R4, R5 and m are as defined in the specification and in the claims, in free form or in salt form, and, where possible, in acid addition salt form, as a vanilloid.
    Type: Application
    Filed: June 8, 2005
    Publication date: August 14, 2008
    Inventors: Timothy John Ritchie, Andrew James Culshaw, Christopher Thomas Brain, Edward Karol Dziadulewicz, Terance William Hart
  • Chromone Derivatives Useful as Vanilloid Antagonists
    Publication number: 20080114056
    Abstract: The present invention relates to the use of a chromone compound of the formula wherein R1, R2, R3, R4, R5 and m are as defined in the specification and in the claims, in free form or in salt form, and, where possible, in acid addition salt form, as a vanilloid antagonist.
    Type: Application
    Filed: June 8, 2005
    Publication date: May 15, 2008
    Inventors: Timothy John Ritchie, Andrew James Culshaw, Terance William Hart, Christopher Thomas Brain, Edward Karol Dziadulewicz
  • Bradykinin receptor antagonists
    Patent number: 6958331
    Abstract: The invention relates to sulfonyl amine derivatives of formula IA wherein R5A, X1, X2, R9 and R10 are as defined herein, which derivatives are useful as bradykinin B1 receptor antagonists.
    Type: Grant
    Filed: June 2, 2000
    Date of Patent: October 25, 2005
    Assignee: Novartis AG
    Inventors: Christopher Thomas Brain, William Cantrell, Andrew James Culshaw, Edward Karol Dziadulewicz, Terance William Hart, Timothy John Ritchie, Liladhar Waykole
  • Naphthalene derivatives
    Publication number: 20040053890
    Abstract: The present invention relates to novel naphthalene derivatives of formula (I), wherein R1, R2, R3 and X are as defined in the description, and preparation thereof. The compounds of formula (I) are useful as pharmaceuticals.
    Type: Application
    Filed: May 19, 2003
    Publication date: March 18, 2004
    Inventors: Christopher Thomas Brain, Andrew James Culshaw, Edward Karol Dziadulewicz, Ulrich Schopfer